APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-dementia Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Anti-dementia Drugs Industry Research Report 2026

27 December 2025144 pages

Choose your research edition.

Industry ResearchAnti-dementia Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-dementia Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-dementia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-dementia Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-dementia Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Anti-dementia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Anti-dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Anti-dementia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Anti-dementia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Anti-dementia Drugs include Eisai Inc., Forest Laboratories, Inc, Niksan Pharmaceutical, Pfizer Inc, Reddy's Laboratories, Anhui Taienkang Pharmaceutical Co., Ltd., Chengdu Tongde Pharmaceutical Co., Ltd., Disa Pharmaceutical Group Co., Ltd. and Jiangsu Hausen Pharmaceutical Group Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Anti-dementia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Anti-dementia Drugs Market by Company

Eisai Inc.

Forest Laboratories, Inc

Niksan Pharmaceutical

Pfizer Inc

Reddy's Laboratories

Anhui Taienkang Pharmaceutical Co., Ltd.

Chengdu Tongde Pharmaceutical Co., Ltd.

Disa Pharmaceutical Group Co., Ltd.

Jiangsu Hausen Pharmaceutical Group Co., Ltd.

Jinri Pharmaceutical (China) Co., Ltd.

Livzon Group Livzon Pharmaceutical Factory

Shandong Luoxin Pharmaceutical Group Co., Ltd.

Shaoxing Jingxin Pharmaceutical Co., Ltd.

Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.

Sichuan Xinston Pharmaceutical Co., Ltd.

Wanquan Wante Pharmaceutical Jiangsu Co., Ltd.

Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd.

Yueyang Xinhuada Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd.

Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Zhejiang Yixin Pharmaceutical Co., Ltd.

Zhien Biotechnology Co., Ltd.

Anti-dementia Drugs Segment by Type

Donepezil

Galantamine

Rivastigmine

Memantine

Other

Anti-dementia Drugs Segment by Application

Clinic

Hospital

Pharmacy

Other

Anti-dementia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-dementia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-dementia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-dementia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Anti-dementia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Anti-dementia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Anti-dementia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Anti-dementia Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Anti-dementia Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Anti-dementia Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Anti-dementia Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Anti-dementia Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Anti-dementia Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Anti-dementia Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Anti-dementia Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Anti-dementia Drugs, Product Type & Application Table 14. Global Anti-dementia Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Anti-dementia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eisai Inc. Company Information Table 19. Eisai Inc. Business Overview Table 20. Eisai Inc. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Eisai Inc. Anti-dementia Drugs Product Portfolio Table 22. Eisai Inc. Recent Developments Table 23. Forest Laboratories, Inc Company Information Table 24. Forest Laboratories, Inc Business Overview Table 25. Forest Laboratories, Inc Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Forest Laboratories, Inc Anti-dementia Drugs Product Portfolio Table 27. Forest Laboratories, Inc Recent Developments Table 28. Niksan Pharmaceutical Company Information Table 29. Niksan Pharmaceutical Business Overview Table 30. Niksan Pharmaceutical Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Niksan Pharmaceutical Anti-dementia Drugs Product Portfolio Table 32. Niksan Pharmaceutical Recent Developments Table 33. Pfizer Inc Company Information Table 34. Pfizer Inc Business Overview Table 35. Pfizer Inc Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Pfizer Inc Anti-dementia Drugs Product Portfolio Table 37. Pfizer Inc Recent Developments Table 38. Reddy's Laboratories Company Information Table 39. Reddy's Laboratories Business Overview Table 40. Reddy's Laboratories Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Reddy's Laboratories Anti-dementia Drugs Product Portfolio Table 42. Reddy's Laboratories Recent Developments Table 43. Anhui Taienkang Pharmaceutical Co., Ltd. Company Information Table 44. Anhui Taienkang Pharmaceutical Co., Ltd. Business Overview Table 45. Anhui Taienkang Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Anhui Taienkang Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 47. Anhui Taienkang Pharmaceutical Co., Ltd. Recent Developments Table 48. Chengdu Tongde Pharmaceutical Co., Ltd. Company Information Table 49. Chengdu Tongde Pharmaceutical Co., Ltd. Business Overview Table 50. Chengdu Tongde Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Chengdu Tongde Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 52. Chengdu Tongde Pharmaceutical Co., Ltd. Recent Developments Table 53. Disa Pharmaceutical Group Co., Ltd. Company Information Table 54. Disa Pharmaceutical Group Co., Ltd. Business Overview Table 55. Disa Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Disa Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio Table 57. Disa Pharmaceutical Group Co., Ltd. Recent Developments Table 58. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information Table 59. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview Table 60. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio Table 62. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments Table 63. Jinri Pharmaceutical (China) Co., Ltd. Company Information Table 64. Jinri Pharmaceutical (China) Co., Ltd. Business Overview Table 65. Jinri Pharmaceutical (China) Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Jinri Pharmaceutical (China) Co., Ltd. Anti-dementia Drugs Product Portfolio Table 67. Jinri Pharmaceutical (China) Co., Ltd. Recent Developments Table 68. Livzon Group Livzon Pharmaceutical Factory Company Information Table 69. Livzon Group Livzon Pharmaceutical Factory Business Overview Table 70. Livzon Group Livzon Pharmaceutical Factory Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Livzon Group Livzon Pharmaceutical Factory Anti-dementia Drugs Product Portfolio Table 72. Livzon Group Livzon Pharmaceutical Factory Recent Developments Table 73. Shandong Luoxin Pharmaceutical Group Co., Ltd. Company Information Table 74. Shandong Luoxin Pharmaceutical Group Co., Ltd. Business Overview Table 75. Shandong Luoxin Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Shandong Luoxin Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio Table 77. Shandong Luoxin Pharmaceutical Group Co., Ltd. Recent Developments Table 78. Shaoxing Jingxin Pharmaceutical Co., Ltd. Company Information Table 79. Shaoxing Jingxin Pharmaceutical Co., Ltd. Business Overview Table 80. Shaoxing Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Shaoxing Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 82. Shaoxing Jingxin Pharmaceutical Co., Ltd. Recent Developments Table 83. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information Table 84. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview Table 85. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 87. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments Table 88. Sichuan Xinston Pharmaceutical Co., Ltd. Company Information Table 89. Sichuan Xinston Pharmaceutical Co., Ltd. Business Overview Table 90. Sichuan Xinston Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sichuan Xinston Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 92. Sichuan Xinston Pharmaceutical Co., Ltd. Recent Developments Table 93. Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Company Information Table 94. Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Business Overview Table 95. Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Anti-dementia Drugs Product Portfolio Table 97. Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Recent Developments Table 98. Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Company Information Table 99. Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Business Overview Table 100. Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 102. Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Recent Developments Table 103. Yueyang Xinhuada Pharmaceutical Co., Ltd. Company Information Table 104. Yueyang Xinhuada Pharmaceutical Co., Ltd. Business Overview Table 105. Yueyang Xinhuada Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Yueyang Xinhuada Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 107. Yueyang Xinhuada Pharmaceutical Co., Ltd. Recent Developments Table 108. Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information Table 109. Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview Table 110. Zhejiang Hisun Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Zhejiang Hisun Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 112. Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments Table 113. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information Table 114. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview Table 115. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 117. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments Table 118. Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Company Information Table 119. Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Business Overview Table 120. Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 122. Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Recent Developments Table 123. Zhejiang Jingxin Pharmaceutical Co., Ltd. Company Information Table 124. Zhejiang Jingxin Pharmaceutical Co., Ltd. Business Overview Table 125. Zhejiang Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Zhejiang Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 127. Zhejiang Jingxin Pharmaceutical Co., Ltd. Recent Developments Table 128. Zhejiang Yixin Pharmaceutical Co., Ltd. Company Information Table 129. Zhejiang Yixin Pharmaceutical Co., Ltd. Business Overview Table 130. Zhejiang Yixin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Zhejiang Yixin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio Table 132. Zhejiang Yixin Pharmaceutical Co., Ltd. Recent Developments Table 133. Zhien Biotechnology Co., Ltd. Company Information Table 134. Zhien Biotechnology Co., Ltd. Business Overview Table 135. Zhien Biotechnology Co., Ltd. Anti-dementia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Zhien Biotechnology Co., Ltd. Anti-dementia Drugs Product Portfolio Table 137. Zhien Biotechnology Co., Ltd. Recent Developments Table 138. Global Anti-dementia Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 139. Global Anti-dementia Drugs Sales by Region (2021-2026) & (K Units) Table 140. Global Anti-dementia Drugs Sales Market Share by Region (2021-2026) Table 141. Global Anti-dementia Drugs Sales by Region (2027-2032) & (K Units) Table 142. Global Anti-dementia Drugs Sales Market Share by Region (2027-2032) Table 143. Global Anti-dementia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 144. Global Anti-dementia Drugs Revenue Market Share by Region (2021-2026) Table 145. Global Anti-dementia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 146. Global Anti-dementia Drugs Revenue Market Share by Region (2027-2032) Table 147. North America Anti-dementia Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. North America Anti-dementia Drugs Sales by Country (2021-2026) & (K Units) Table 149. North America Anti-dementia Drugs Sales by Country (2027-2032) & (K Units) Table 150. North America Anti-dementia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Anti-dementia Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Europe Anti-dementia Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Europe Anti-dementia Drugs Sales by Country (2021-2026) & (K Units) Table 154. Europe Anti-dementia Drugs Sales by Country (2027-2032) & (K Units) Table 155. Europe Anti-dementia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Anti-dementia Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Asia Pacific Anti-dementia Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Asia Pacific Anti-dementia Drugs Sales by Country (2021-2026) & (K Units) Table 159. Asia Pacific Anti-dementia Drugs Sales by Country (2027-2032) & (K Units) Table 160. Asia Pacific Anti-dementia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 161. Asia Pacific Anti-dementia Drugs Revenue by Country (2027-2032) & (US$ Million) Table 162. South America Anti-dementia Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. South America Anti-dementia Drugs Sales by Country (2021-2026) & (K Units) Table 164. South America Anti-dementia Drugs Sales by Country (2027-2032) & (K Units) Table 165. South America Anti-dementia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 166. South America Anti-dementia Drugs Revenue by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Anti-dementia Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Middle East and Africa Anti-dementia Drugs Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa Anti-dementia Drugs Sales by Country (2027-2032) & (K Units) Table 170. Middle East and Africa Anti-dementia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Anti-dementia Drugs Revenue by Country (2027-2032) & (US$ Million) Table 172. Global Anti-dementia Drugs Sales by Type (2021-2026) & (K Units) Table 173. Global Anti-dementia Drugs Sales by Type (2027-2032) & (K Units) Table 174. Global Anti-dementia Drugs Sales Market Share by Type (2021-2026) Table 175. Global Anti-dementia Drugs Sales Market Share by Type (2027-2032) Table 176. Global Anti-dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 177. Global Anti-dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 178. Global Anti-dementia Drugs Revenue Market Share by Type (2021-2026) Table 179. Global Anti-dementia Drugs Revenue Market Share by Type (2027-2032) Table 180. Global Anti-dementia Drugs Price by Type (2021-2026) & (US$/Unit) Table 181. Global Anti-dementia Drugs Price by Type (2027-2032) & (US$/Unit) Table 182. Global Anti-dementia Drugs Sales by Application (2021-2026) & (K Units) Table 183. Global Anti-dementia Drugs Sales by Application (2027-2032) & (K Units) Table 184. Global Anti-dementia Drugs Sales Market Share by Application (2021-2026) Table 185. Global Anti-dementia Drugs Sales Market Share by Application (2027-2032) Table 186. Global Anti-dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 187. Global Anti-dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 188. Global Anti-dementia Drugs Revenue Market Share by Application (2021-2026) Table 189. Global Anti-dementia Drugs Revenue Market Share by Application (2027-2032) Table 190. Global Anti-dementia Drugs Price by Application (2021-2026) & (US$/Unit) Table 191. Global Anti-dementia Drugs Price by Application (2027-2032) & (US$/Unit) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Anti-dementia Drugs Distributors List Table 195. Anti-dementia Drugs Customers List Table 196. Anti-dementia Drugs Industry Trends Table 197. Anti-dementia Drugs Industry Drivers Table 198. Anti-dementia Drugs Industry Restraints Table 199. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Anti-dementia Drugs Product Image Figure 5. Global Anti-dementia Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Anti-dementia Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Anti-dementia Drugs Sales (2021-2032) & (K Units) Figure 8. Global Anti-dementia Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Donepezil Product Image Figure 10. Galantamine Product Image Figure 11. Rivastigmine Product Image Figure 12. Memantine Product Image Figure 13. Other Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Pharmacy Product Image Figure 17. Other Product Image Figure 18. Global Anti-dementia Drugs Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Anti-dementia Drugs, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Anti-dementia Drugs Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Anti-dementia Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Anti-dementia Drugs Sales by Region in 2025 Figure 24. Global Anti-dementia Drugs Revenue by Region in 2025 Figure 25. North America Anti-dementia Drugs Market Size by Country in 2025 Figure 26. North America Anti-dementia Drugs Sales Market Share by Country (2021-2032) Figure 27. North America Anti-dementia Drugs Revenue Market Share by Country (2021-2032) Figure 28. United States Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Anti-dementia Drugs Market Size by Country in 2025 Figure 32. Europe Anti-dementia Drugs Sales Market Share by Country (2021-2032) Figure 33. Europe Anti-dementia Drugs Revenue Market Share by Country (2021-2032) Figure 34. Germany Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Anti-dementia Drugs Market Size by Country in 2025 Figure 45. Asia Pacific Anti-dementia Drugs Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Anti-dementia Drugs Revenue Market Share by Country (2021-2032) Figure 47. China Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Anti-dementia Drugs Market Size by Country in 2025 Figure 56. South America Anti-dementia Drugs Sales Market Share by Country (2021-2032) Figure 57. South America Anti-dementia Drugs Revenue Market Share by Country (2021-2032) Figure 58. Brazil Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Anti-dementia Drugs Market Size by Country in 2025 Figure 62. Middle East and Africa Anti-dementia Drugs Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Anti-dementia Drugs Revenue Market Share by Country (2021-2032) Figure 64. Egypt Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Anti-dementia Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Anti-dementia Drugs Sales Market Share by Type (2021-2032) Figure 70. Global Anti-dementia Drugs Revenue Market Share by Type (2021-2032) Figure 71. Global Anti-dementia Drugs Price (US$/Unit) by Type (2021-2032) Figure 72. Global Anti-dementia Drugs Sales Market Share by Application (2021-2032) Figure 73. Global Anti-dementia Drugs Revenue Market Share by Application (2021-2032) Figure 74. Global Anti-dementia Drugs Price (US$/Unit) by Application (2021-2032) Figure 75. Anti-dementia Drugs Value Chain Figure 76. Anti-dementia Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Anti-dementia Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Other
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Eisai Inc.
  • Forest Laboratories, Inc
  • Niksan Pharmaceutical
  • Pfizer Inc
  • Reddy's Laboratories
  • Anhui Taienkang Pharmaceutical Co., Ltd.
  • Chengdu Tongde Pharmaceutical Co., Ltd.
  • Disa Pharmaceutical Group Co., Ltd.
  • Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  • Jinri Pharmaceutical (China) Co., Ltd.
  • Livzon Group Livzon Pharmaceutical Factory
  • Shandong Luoxin Pharmaceutical Group Co., Ltd.
  • Shaoxing Jingxin Pharmaceutical Co., Ltd.
  • Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
  • Sichuan Xinston Pharmaceutical Co., Ltd.
  • Wanquan Wante Pharmaceutical Jiangsu Co., Ltd.
  • Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd.
  • Yueyang Xinhuada Pharmaceutical Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.
  • Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • Zhejiang Yixin Pharmaceutical Co., Ltd.
  • Zhien Biotechnology Co., Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Anti-dementia Drugs Market Size (2021-2032)
  4. 2.2.2 Global Anti-dementia Drugs Sales (2021-2032)
  5. 2.2.3 Global Anti-dementia Drugs Market Average Price (2021-2032)
  6. 2.3 Anti-dementia Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Donepezil
  9. 2.3.3 Galantamine
  10. 2.3.4 Rivastigmine
  11. 2.3.5 Memantine
  12. 2.3.6 Other
  13. 2.4 Anti-dementia Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Pharmacy
  18. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Anti-dementia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Anti-dementia Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Anti-dementia Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Anti-dementia Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Anti-dementia Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Anti-dementia Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Anti-dementia Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Anti-dementia Drugs, Established Date
  9. 3.9 Global Anti-dementia Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eisai Inc.
  2. 4.1.1 Eisai Inc. Company Information
  3. 4.1.2 Eisai Inc. Business Overview
  4. 4.1.3 Eisai Inc. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eisai Inc. Anti-dementia Drugs Product Portfolio
  6. 4.1.5 Eisai Inc. Recent Developments
  7. 4.2 Forest Laboratories, Inc
  8. 4.2.1 Forest Laboratories, Inc Company Information
  9. 4.2.2 Forest Laboratories, Inc Business Overview
  10. 4.2.3 Forest Laboratories, Inc Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Forest Laboratories, Inc Anti-dementia Drugs Product Portfolio
  12. 4.2.5 Forest Laboratories, Inc Recent Developments
  13. 4.3 Niksan Pharmaceutical
  14. 4.3.1 Niksan Pharmaceutical Company Information
  15. 4.3.2 Niksan Pharmaceutical Business Overview
  16. 4.3.3 Niksan Pharmaceutical Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Niksan Pharmaceutical Anti-dementia Drugs Product Portfolio
  18. 4.3.5 Niksan Pharmaceutical Recent Developments
  19. 4.4 Pfizer Inc
  20. 4.4.1 Pfizer Inc Company Information
  21. 4.4.2 Pfizer Inc Business Overview
  22. 4.4.3 Pfizer Inc Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Inc Anti-dementia Drugs Product Portfolio
  24. 4.4.5 Pfizer Inc Recent Developments
  25. 4.5 Reddy's Laboratories
  26. 4.5.1 Reddy's Laboratories Company Information
  27. 4.5.2 Reddy's Laboratories Business Overview
  28. 4.5.3 Reddy's Laboratories Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Reddy's Laboratories Anti-dementia Drugs Product Portfolio
  30. 4.5.5 Reddy's Laboratories Recent Developments
  31. 4.6 Anhui Taienkang Pharmaceutical Co., Ltd.
  32. 4.6.1 Anhui Taienkang Pharmaceutical Co., Ltd. Company Information
  33. 4.6.2 Anhui Taienkang Pharmaceutical Co., Ltd. Business Overview
  34. 4.6.3 Anhui Taienkang Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Anhui Taienkang Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  36. 4.6.5 Anhui Taienkang Pharmaceutical Co., Ltd. Recent Developments
  37. 4.7 Chengdu Tongde Pharmaceutical Co., Ltd.
  38. 4.7.1 Chengdu Tongde Pharmaceutical Co., Ltd. Company Information
  39. 4.7.2 Chengdu Tongde Pharmaceutical Co., Ltd. Business Overview
  40. 4.7.3 Chengdu Tongde Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Chengdu Tongde Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  42. 4.7.5 Chengdu Tongde Pharmaceutical Co., Ltd. Recent Developments
  43. 4.8 Disa Pharmaceutical Group Co., Ltd.
  44. 4.8.1 Disa Pharmaceutical Group Co., Ltd. Company Information
  45. 4.8.2 Disa Pharmaceutical Group Co., Ltd. Business Overview
  46. 4.8.3 Disa Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Disa Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio
  48. 4.8.5 Disa Pharmaceutical Group Co., Ltd. Recent Developments
  49. 4.9 Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  50. 4.9.1 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information
  51. 4.9.2 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview
  52. 4.9.3 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio
  54. 4.9.5 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments
  55. 4.10 Jinri Pharmaceutical (China) Co., Ltd.
  56. 4.10.1 Jinri Pharmaceutical (China) Co., Ltd. Company Information
  57. 4.10.2 Jinri Pharmaceutical (China) Co., Ltd. Business Overview
  58. 4.10.3 Jinri Pharmaceutical (China) Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Jinri Pharmaceutical (China) Co., Ltd. Anti-dementia Drugs Product Portfolio
  60. 4.10.5 Jinri Pharmaceutical (China) Co., Ltd. Recent Developments
  61. 4.11 Livzon Group Livzon Pharmaceutical Factory
  62. 4.11.1 Livzon Group Livzon Pharmaceutical Factory Company Information
  63. 4.11.2 Livzon Group Livzon Pharmaceutical Factory Business Overview
  64. 4.11.3 Livzon Group Livzon Pharmaceutical Factory Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Livzon Group Livzon Pharmaceutical Factory Anti-dementia Drugs Product Portfolio
  66. 4.11.5 Livzon Group Livzon Pharmaceutical Factory Recent Developments
  67. 4.12 Shandong Luoxin Pharmaceutical Group Co., Ltd.
  68. 4.12.1 Shandong Luoxin Pharmaceutical Group Co., Ltd. Company Information
  69. 4.12.2 Shandong Luoxin Pharmaceutical Group Co., Ltd. Business Overview
  70. 4.12.3 Shandong Luoxin Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Shandong Luoxin Pharmaceutical Group Co., Ltd. Anti-dementia Drugs Product Portfolio
  72. 4.12.5 Shandong Luoxin Pharmaceutical Group Co., Ltd. Recent Developments
  73. 4.13 Shaoxing Jingxin Pharmaceutical Co., Ltd.
  74. 4.13.1 Shaoxing Jingxin Pharmaceutical Co., Ltd. Company Information
  75. 4.13.2 Shaoxing Jingxin Pharmaceutical Co., Ltd. Business Overview
  76. 4.13.3 Shaoxing Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Shaoxing Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  78. 4.13.5 Shaoxing Jingxin Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
  80. 4.14.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
  81. 4.14.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
  82. 4.14.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  84. 4.14.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Sichuan Xinston Pharmaceutical Co., Ltd.
  86. 4.15.1 Sichuan Xinston Pharmaceutical Co., Ltd. Company Information
  87. 4.15.2 Sichuan Xinston Pharmaceutical Co., Ltd. Business Overview
  88. 4.15.3 Sichuan Xinston Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sichuan Xinston Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  90. 4.15.5 Sichuan Xinston Pharmaceutical Co., Ltd. Recent Developments
  91. 4.16 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd.
  92. 4.16.1 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Company Information
  93. 4.16.2 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Business Overview
  94. 4.16.3 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Anti-dementia Drugs Product Portfolio
  96. 4.16.5 Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. Recent Developments
  97. 4.17 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd.
  98. 4.17.1 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Company Information
  99. 4.17.2 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Business Overview
  100. 4.17.3 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  102. 4.17.5 Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. Recent Developments
  103. 4.18 Yueyang Xinhuada Pharmaceutical Co., Ltd.
  104. 4.18.1 Yueyang Xinhuada Pharmaceutical Co., Ltd. Company Information
  105. 4.18.2 Yueyang Xinhuada Pharmaceutical Co., Ltd. Business Overview
  106. 4.18.3 Yueyang Xinhuada Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Yueyang Xinhuada Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  108. 4.18.5 Yueyang Xinhuada Pharmaceutical Co., Ltd. Recent Developments
  109. 4.19 Zhejiang Hisun Pharmaceutical Co., Ltd.
  110. 4.19.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
  111. 4.19.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
  112. 4.19.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  114. 4.19.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
  115. 4.20 Zhejiang Huahai Pharmaceutical Co., Ltd.
  116. 4.20.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
  117. 4.20.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
  118. 4.20.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  120. 4.20.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
  121. 4.21 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.
  122. 4.21.1 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Company Information
  123. 4.21.2 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Business Overview
  124. 4.21.3 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  126. 4.21.5 Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. Recent Developments
  127. 4.22 Zhejiang Jingxin Pharmaceutical Co., Ltd.
  128. 4.22.1 Zhejiang Jingxin Pharmaceutical Co., Ltd. Company Information
  129. 4.22.2 Zhejiang Jingxin Pharmaceutical Co., Ltd. Business Overview
  130. 4.22.3 Zhejiang Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Zhejiang Jingxin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  132. 4.22.5 Zhejiang Jingxin Pharmaceutical Co., Ltd. Recent Developments
  133. 4.23 Zhejiang Yixin Pharmaceutical Co., Ltd.
  134. 4.23.1 Zhejiang Yixin Pharmaceutical Co., Ltd. Company Information
  135. 4.23.2 Zhejiang Yixin Pharmaceutical Co., Ltd. Business Overview
  136. 4.23.3 Zhejiang Yixin Pharmaceutical Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Zhejiang Yixin Pharmaceutical Co., Ltd. Anti-dementia Drugs Product Portfolio
  138. 4.23.5 Zhejiang Yixin Pharmaceutical Co., Ltd. Recent Developments
  139. 4.24 Zhien Biotechnology Co., Ltd.
  140. 4.24.1 Zhien Biotechnology Co., Ltd. Company Information
  141. 4.24.2 Zhien Biotechnology Co., Ltd. Business Overview
  142. 4.24.3 Zhien Biotechnology Co., Ltd. Anti-dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Zhien Biotechnology Co., Ltd. Anti-dementia Drugs Product Portfolio
  144. 4.24.5 Zhien Biotechnology Co., Ltd. Recent Developments
5 Global Anti-dementia Drugs Market Scenario by Region
  1. 5.1 Global Anti-dementia Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Anti-dementia Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Anti-dementia Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Anti-dementia Drugs Sales by Region: 2027-2032
  5. 5.3 Global Anti-dementia Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Anti-dementia Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Anti-dementia Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Anti-dementia Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Anti-dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Anti-dementia Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Anti-dementia Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Anti-dementia Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Anti-dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Anti-dementia Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Anti-dementia Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Anti-dementia Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Anti-dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Anti-dementia Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Anti-dementia Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Anti-dementia Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Anti-dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Anti-dementia Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Anti-dementia Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Anti-dementia Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Anti-dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Anti-dementia Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Anti-dementia Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Anti-dementia Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Anti-dementia Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Anti-dementia Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Anti-dementia Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Anti-dementia Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Anti-dementia Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Anti-dementia Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Anti-dementia Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Anti-dementia Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Anti-dementia Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Anti-dementia Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Anti-dementia Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Anti-dementia Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Anti-dementia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Anti-dementia Drugs Value Chain Analysis
  2. 8.1.1 Anti-dementia Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Anti-dementia Drugs Production Mode & Process
  5. 8.2 Anti-dementia Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Anti-dementia Drugs Distributors
  8. 8.2.3 Anti-dementia Drugs Customers
9 Global Anti-dementia Drugs Analyzing Market Dynamics
  1. 9.1 Anti-dementia Drugs Industry Trends
  2. 9.2 Anti-dementia Drugs Industry Drivers
  3. 9.3 Anti-dementia Drugs Industry Opportunities and Challenges
  4. 9.4 Anti-dementia Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst